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Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor
(GM-CSF) bothmobilize CD34þ stem cells into the blood when administered before apheresis but have distinct
effects on dendritic cell (DC) differentiation. We previously demonstrated that the combination of GMþG-CSF
results in fewer plasmacytoid DCs (pDCs) when used to mobilize peripheral blood stem cells for autologous
transplantation. To test the hypothesis that the content of pDCs in an allograft can be modulated with the
cytokines used for mobilization, we randomized the human leukocyte antigenematched sibling donors of 50
patients with hematological malignancies to a mobilization regimen of either GMþG-CSF (n ¼ 25) or G-CSF
alone (n¼ 25). Primary and secondary endpoints included the cellular constituents of the mobilized grafts, the
kinetics of posttransplantation immune reconstitution, and clinical outcomes of the transplantation recipi-
ents. Grafts from donors receiving GMþG-CSF contained equivalent numbers of CD34þ cells with fewer pDCs
and T cells, with a higher fraction of Th1-polarized donor T cells than G-CSFmobilized grafts. Immune recovery
was enhanced among recipients of GMþG-CSF. Survival was not signiﬁcantly different between trans-
plantation recipients in the two arms. The use of GMþG-CSF modulates immune function and recovery after
allogeneic transplantation and should be explored in larger studies powered to evaluate clinical outcomes.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION counterparts express high levels of the same costimulatory
Restoration of normal immune homeostasis after alloge-
neic hematopoietic stem cell transplantation (HSCT) requires
engraftment and expansion of donor T cells contained in the
graft and differentiation of immune cells from donor hema-
topoietic progenitors. Donor T cell activation and prolifera-
tion is regulated, in part, by speciﬁc subsets of donor
dendritic cells (DCs) contained in the allograft [1]. The
differentiation of speciﬁc DC subsets from CD34þ stem cells
is regulated by myeloid cytokines [2,3]. CD34þ stem cells
cultured with interleukin (IL)-3 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) differen-
tiate into Lin-/HLA-DRþ/CD11cþ/CD123 “myeloid” dendritic
cell progenitors (mDC), whereas stem cells culturedwith IL-3
and granulocyte colony-stimulating factor (G-CSF) differen-
tiate into Lin/HLA-DRþ/CD11c/CD123þ plasmacytoid
dendritic cell progenitors (pDC) [4]. Immature progenitor
DCs express very low levels of CD80, CD86, and CD40 and are
highly effective at antigen processing, whereas their matureedgment on page 466.
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12.11.017molecules and are highly efﬁcient at antigen presentation
[5]. Maturation of both types of DC progenitors occurs after
exposure to tumor necrosis factor-a or CD-40L [3].
The clinical signiﬁcance of the content of donor DCs in
a hematopoietic stem cell graft has been the subject of
several analyses, with conﬂicting results. Our group reported
that recipients of allogeneic bone marrow grafts containing
a higher proportion of pDCs had a higher relapse rate, less
chronic graft-versus-host disease (cGVHD), and poorer
event-free survival rates compared with grafts containing
fewer pDCs [6]. Patients who underwent peripheral blood
progenitor cell transplantation with grafts mobilized with
GM-CSF from human leukocyte antigen (HLA)-matched
siblings developed less grade II-IV acute GVHD (aGVDH) than
a comparable historical group that received grafts mobilized
with G-CSF [7]. It has been established that G-CSF mobili-
zation results in increased frequencies of pDCs in the stem
cell graft [8], and a randomized clinical study of mobilization
of patients undergoing autologous transplantations demon-
strated that stem cell grafts mobilized with the combination
of GMþG-CSF contained fewer pDCs than grafts mobilized
with G-CSF alone [9]. What remains unknown from clinical
studies is the impact of mobilization cytokines on post-
transplantation T cell function, polarization, immune
recovery, and clinical outcomes such as GVHD and infections.Transplantation.
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obtained from nonmobilized blood, our group demonstrated
that pDCs inhibit Th1 cell responses of syngeneic T cells after
indirect antigen presentation of alloantigens [10]. Interest-
ingly, the mechanical removal of pDCs from blood mono-
nuclear cells using immunoafﬁnity columns results in
increased proliferation of the T cells in response to alloan-
tigen, suggesting that pDCs may be limiting or controlling
T cell proliferation in response to antigen via induction of
regulatory T cells. Taken together, these data suggested that
changes in the numbers of mDCs and pDCs in an allogeneic
hematopoietic progenitor cell graft might result in clinically
signiﬁcant changes in posttransplantation immune recon-
stitution among patients undergoing allogeneic HSCT for
hematological malignancies.
To test the hypothesis that mobilization with a GM-
CSFecontaining regimen alters the DC content of the graft
and changes the posttransplantation immune reconstitution,
we initiated a randomized clinical trial in patients with
hematological malignancies undergoing allogeneic stem cell
transplantation. HLA-matched sibling donors were random-
ized to receive a standard 5-day course of G-CSF or the
combination of GMþG-CSF before apheresis and collection of
an allogeneic blood hematopoietic progenitor cell graft.
METHODS
Patients and Donors
Fifty patients with hematological malignancies whowere candidates for
high-dose chemotherapy and allogeneic HSCT and their HLA-matched
sibling donors were enrolled in a prospective, institutional review
boardeapproved clinical trial after both donor and recipients provided
informed consent. The hematological malignancies represented in enrolled
transplantation recipients were as follows: acute myelogenous leukemia,
non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic myeloge-
nous leukemia, chronic lymphocytic leukemia, and biphenotypic leukemia.
Patients with acute lymphoblastic leukemia in ﬁrst complete remission,
acute myelogenous leukemia in ﬁrst complete remission, chronic myelog-
enous leukemia in ﬁrst chronic phase, and myelodysplastic syndrome with
refractory anemia or with refractory anemia with ringed sideroblasts were
classiﬁed as low risk for transplantation death or relapse; all other patients
were considered high risk.
Randomization of the donors was stratiﬁed based on the risk strata
(high or low) of the recipient. Two weeks after collection of the stem cell
graft, donors were given a questionnaire regarding any toxicities experi-
enced during administration of cytokines. These questions speciﬁcally
included the following symptoms known to be associated with the
administration of G-CSF and GM-CSF: bone pain, fever, myalgias, skin
reactions, chills, and ﬂushing. Answers were graded using CTC version 2.0.
These data were individually tabulated for each treatment arm. Patients
did not receive posttransplantation cytokines to hasten hematopoietic
recovery per institutional standard. Additionally, no patients received
planned or pre-emptive donor lymphocyte infusion as part of their trans-
plantation plan.
Stem Cell Mobilization and Collection
Donors were randomized to receive either twice-daily subcutaneous
injections of G-CSF (7.5 mg/kg twice daily; cohort A) or daily injections of the
combination of G-CSF (7.5 mg/kg) eachmorning and GM-CSF (7.5 mg/kg) each
evening (cohort B). Side effects from the two regimens were evaluated using
a standardized format of questions to determine differences in side effects
between the two randomized arms. Large-volume apheresis (24 L) with
a COBE (Lakewood, CO) apheresis unit was initiated on the 5th day of
cytokine administration. Daily growth factor administration and apheresis
was continued until the target CD34 dose of 5  106/kg were collected, or 4
days of apheresis were performed. A minimum dose of 3  106 CD34þ cells/
kg was required for patients to proceed to allogeneic transplantation.
Analysis of Graft Constituents
Mononuclear cells in the apheresis sample were separated by centri-
fugation over Ficoll-Hypaque. The cells were then resuspended in 100 mL of
staining media at a concentration of 107 cells total/100mL. Extracellular
staining was performed in a standard fashion by using antibodies against
CD3, CD4, CD8, CD11c, CD123, CD34, CD38, CD56, CD16, and HLA-DR (BectonDickinson, Franklin Lakes, NJ); CD34þ cells, T cell subsets, and DC subsets
were deﬁned according to previously described methods [11,12]. We used
the multigating strategy to identify pDCs and mDCs because BDCA1 and
BDCA2 antibodies were not in routine clinical use at the time the study
began and thus were not available for routine ﬂow cytometry. However,
there is a very high correlation (R ¼ .914) between the use of the BDCA
antibodies and the gating strategy we used for the DC analysis in the current
study [13].Analysis of Posttransplantation Immune Reconstitution
Blood immune cells were monitored at 2-month intervals after HSCT as
part of the standard care for stem cell transplantation patients at this
institution. Fresh blood samples were analyzed immediately after collection,
with processing, antibody staining, and ﬂow cytometry performed by the
clinical laboratory. The percentages of blood pDCs (Lin, CD123þ, CD11c,
HLA-DRþ), mDCs (Lin, CD123, CD11cþ, HLA-DRþ), CD4þ, CD8þ, CD16þ,
CD19þ, and CD56þ cells in peripheral blood mononuclear cells were
measured by ﬂowcytometry in the clinical laboratory. Cell phenotyping data
were combined with the white blood cell count to calculate the total
number of each cell type per microliter of blood.
From 2002 to 2006, ﬂow cytometry data were acquired using a Becton
Dickinson FACS Calibur instrument, and after 2006, data were acquired on
a Becton Dickinson FACS Canto or FACS Canto II instrument. Becton Dick-
inson Cell Quest software was used for analysis of all ﬂow cytometry data.
Peripheral blood mononuclear cells were placed in fresh media for 16 hours
with T cell mitogen phorbol myristate acetate/ionomycin. A protein trans-
port inhibitor (Golgistop; Pharmingen, San Diego, CA) was added for an
additional 5 hours by using conditions speciﬁed by the supplier. Cells were
assayed for simultaneous expression of T cell markers (CD3, CD4, or CD8)
and intracellular cytokine production (IL-2, IL-4, IL-12, IL-10, interferon-g, or
tumor necrosis factor-a) in the mononuclear cells with appropriate
ﬂuorochrome-conjugated monoclonal antibodies, isotype controls, and
CytoFix/CytoPerm reagents (Pharmingen).
List mode ﬁles were acquired and analyzed with CellQuest software.
Samples were considered to be positive for cytokine expression if the
frequency of positively stained cells using antibodies to cytokines was at
least twofold greater than that of the isotype control.Statistical Comparisons
Sample size determinations for this randomized trial were based on
a baseline frequency of mDCs and pDCs within the peripheral blood of .5%
with a standard deviation equal to the mean (.5%). Based on the previously
conducted autologous mobilization study [9], we anticipated a 50% reduc-
tion in the content of pDCs in the grafts collected from donors randomized
to receive the GMþG-CSF regimen and included 25 patients in each arm to
detect the predicted reduction in pDC content with a power of 90%. The two-
sample Wilcoxon signed-rank test was used to determine whether the
median numbers of prespeciﬁed cell subsets in the allograft collected from
the treatment groupswere the same (CD34þ, T cell subsets, DC subsets). The
standard error of the meanwas used to represent variance from the mean in
each treatment group. Median survival, progression-free survival, relapse
rates, and GVHD rates between the two treatment arms were compared
using the log rank test. Cox regression models were used in the multivari-
able analysis. The P value from the Wald test was calculated for the global
test of Cox models. Each Cox model included the treatment arm and one
other covariate.RESULTS
Stem Cell Collection
Fifty donorerecipient pairs were randomized to receive
cytokine mobilization with either G-CSF alone (cohort A;
n ¼ 25) or the combination of GMþG-CSF (cohort B; n ¼ 25)
between October 2002 and November 2006. Baseline char-
acteristics were balanced between the two treatment arms,
except recipients of the G-CSFmobilized graft were older and
thus were more likely to receive conditioning with busulfan-
cyclophosphamide (Table 1). Patients were stratiﬁed by
disease risk, and adequate numbers of hematopoietic
progenitor cells were successfully collected from all 50
donors. One donor in the combination arm had GM-CSF
discontinued on day 4 due to fever and fatigue. Seventy-
two percent of the recipients in the trial were considered
high risk (Table 1).
Table 1
Baseline Patient Characteristics
Variable G-CSF Arm
(Cohort A)
GMþG-CSF Arm
(Cohort B)
Total 25 25
Recipient age, y, median (range) 53 (24-69) 43 (22-64)*
Sex
Male 10 14
Female 15 11
Donor age, y, median (range) 51 (30-73) 39 (18-62)y
Sex
Male 11 21
Female 14 4
Disease
Acute myelogenous leukemia 14 6
Non-Hodgkin lymphoma 5 5
Acute lymphoblastic leukemia 1 5
Myelodysplastic syndrome 2 3
Chronic myelogenous leukemia 2 2
Hodgkin Disease 0 2
Chronic lymphocytic leukemia 1 1
Biphenotypic leukemia 0 1
Risk group
Low 6 7
High 19 18
Conditioning regimen
Busulfan-Cy 10 6
TBI-Cy (þantithymocyte globulin) 5 11 (2)
Flu þ (Mel/Cy/TBI/Ara-C) 10 8
Cy indicates cyclophosphamide; TBI, total body irradiation; Flu, ﬂudarabine;
Mel, melphalan; Ara-C, cytarabine.
* P ¼ .02.
y P < .001.
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Figure 1. Differences in total T cell and T cell subsets within grafts mobilized
with either G-CSF or GMþG-CSF. Values represent mean  standard error of
the mean (SEM). *P < .01.
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average number of apheresis days was 1.08 þ .28 compared
with 1.40 þ .71 in the group receiving G-CSF (P¼ .02). Two of
25 donors in the GMþG-CSF group required more than one
apheresis session, whereas 10 of 25 donors in the G-CSF
group required more than one apheresis session to collect
3  106 CD34þ cells/kg, although this difference in days to
collect could be a consequence of the older donor ages
among the donors who received G-CSF alone as compared
with the group that received GMþG-CSF (Table 1).
Cytokine-Related Adverse Events
After successful mobilization of peripheral blood stem
cells, donors were given a side effect questionnaire (Table 2).
Among those that answered (17 in theG-CSFarmand23 in the
GMþG-CSF arm), there was a higher incidence of fever, bone
and joint pain, headache, and overall symptoms in the group
that received GMþG-CSF. There were three grade 3 toxicities
in the GMþG-CSF group (two reports of headache and one of
bone pain) and one grade 3 toxicity in the group that received
G-CSF (headache). Other adverse events included increased
fatigue, chills, insomnia (all grade 1), and deep venous
thrombosis (in 1 patient), all in those who received GMþG-
CSF. Although numeric differences were seen in the number
of cytokine-related adverse events, with a higher numberTable 2
Patient-Reported Symptoms as Described in a Questionnaire after Collection
of Cells
Treatment
Group
n Fever Bone Pain Injection
Site Pain
Injection
Site Red
HA
G-CSF 17 2 12 2 1 7
GMþG-CSF 23 9 19 5 3 9
HA indicates Headache.occurring among patients receiving GMþG-CSF, there was no
statistical difference between the frequency of events, likely
a consequence of a smaller sample size. Only one patient had
to discontinue cytokine administration as a consequence of an
adverse event (GMþG-CSF arm).
Graft Constituents
Comparison of graft constituents in the apheresis prod-
ucts collected from the two groups of donors revealed similar
numbers of CD34þ cells in the two groups and fewer CD3þ T
cells and T cell subsets in the donors randomized to receive
the combination of GMþG-CSF. Both CD4þ and CD8þ T cells
were reduced in the GM þG-CSF group, suggesting no pref-
erential reduction of any T cell subsets (Figure 1). As
hypothesized, the content of pDCs in the grafts collected
from donors mobilized with GMþG-CSF were signiﬁcantly
lower compared with the grafts mobilized by G-CSF alone
(P < .001) (Figure 2). There were no other signiﬁcant differ-
ences between cellular constituents of the grafts among the
cytokine groups.
Immune Polarization of Cells in the Graft and Post-
Transplantation Immune Reconstitution
Signiﬁcantly more secretion of IL-12 was found in
response to mitogen stimulation from the mononuclear cells0
2
CD34 pDC mDC
Cell Subset (mean)
Figure 2. Differences in CD34þ, pDC, and mDC, mobilization of matched
related donor grafts using either G-CSF or GMþG-CSF. Values represent
mean  standard error of the mean (SEM). *P < .05. Difference in CD34 and
mDC was not statistically signiﬁcant.
Figure 3. Secreted cytokines in response to mitogen from the collected graft. Values represent mean  standard error of the mean (SEM). *P < .05. PMA, phorbol
myristate acetate; PWM, pokeweed mitogen.
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compared with grafts collected with G-CSF alone, although
grafts mobilized with G-CSF alone did secrete more IL-2 in
response to phorbol myristate acetate/ionomycin (Figure 3).
At the time of graft collection, there was not a signiﬁcant
difference in cytokine secretion when IL-4, IL-10, interferon-
g, or tumor necrosis factor-a were measured at the same
time point (data not shown). Cytokine secretion was also
tested at day þ20 posttransplantation, and no difference was
noted in the cytokine proﬁle between the two treatment
groups (data not shown).
The numbers of blood pDCs, mDCs, CD4þ, CD8þ, CD16þ,
CD19þ, and CD56þ cells in peripheral bloodwere determined
by ﬂow cytometry at months 2, 4, 6, 8, and 12 after the HSCT.
The group receiving grafts mobilized with GMþG-CSF had
more CD4þ T cells in blood compared with the group
receiving G-CSF mobilized grafts at all measured time point
intervals (1-2 months, P ¼ .0008; 3-4 months, P ¼ .011; 5-6
months; P ¼ .0021; 7-8 months, P ¼ .17; 10-12 months,
P ¼ .00041) (Figure 4B). The only other measured cell
difference occurred at the 6-month time point, when CD16þ
cells were higher among recipients of GMþG-CSF mobilized
grafts (Figure 4D). There was no difference in total T cell
recovery (Figure 4A, B, and C), B cell recovery (Figure 4E), or
DC recovery (Figure 4F, G).
Posttransplantation Hematopoietic Engraftment, GVHD,
and Infectious Complications
Neutrophil and platelet engraftment were achieved in all
recipients, with no signiﬁcant differences between treatment
arms. The incidence of aGVHD and cGVHD was similar
between patients in both treatment arms (Table 3). In the
experimental arm (GMþG-CSF), 7 patients developed at least
grade II aGVHD, and 10 patients developed cGVHD (7 with
extensive and 3 with limited stage). In the group that
received grafts mobilized with G-CSF, 10 developed at least
grade II aGVHD, and 11 patients developed cGVHD (8 with
extensive and 3 with limited stage). From the perspective of
posttransplantation infectious complications that required
hospitalization, 11 patients developed either a bacterial or
viral infection in the G-CSF arm, compared with 7 in the
GMþG-CSF arm (P ¼ ns). When viral infections were
reviewed speciﬁcally, two patients in each arm developed
cytomegalovirus reactivation; one patient in the G-CSF armdeveloped cytomegalovirus disease (enteritis), and one
patient in the G-CSF arm developed BK viruseinduced
hemorrhagic cystitis. One patient in each arm developed
varicella-zoster virus reactivation.
Posttransplantation Relapse and Survival
Twenty deaths occurred in the experimental arm
(GM þG-CSF) versus 14 deaths in the control arm (G-CSF), as
detailed in Table 3. Median survival for recipients of grafts
mobilizedwith GMþG-CSFwas 7.3months and for recipients
of grafts mobilized with G-CSF was 38.3 months at the time
of last follow-up; the median duration of follow-up was
60 months. A statistically signiﬁcant difference was not
found between the two groups (P ¼ .08, Wilcoxon test)
(Figure 5). Also, no signiﬁcant differences were found in
progression-free survival between the two groups (P ¼ .118,
Wilcoxon test).
DISCUSSION
This randomized clinical trial was performed to test the
hypothesis that cytokines could have differential effects on
the mobilization of DC subsets. We analyzed the DC content
of apheresis products and evaluated the frequency of
cytokine-related adverse events among patients randomized
to receive G-CSF alone or GMþG-CSF. Our hypothesis was
that GM-CSFecontaining regimens would result in fewer
pDCs in the apheresis product based on data from Arpinati
et al. [8] that G-CSF mobilizes more pDCs in the blood and
that GM-CSF is required to differentiate human HSCs into
mDCs. Thus, we extrapolated that combination of GMþG-CSF
would result in fewer pDCs in the blood HSC graft compared
with mobilization using G-CSF alone [14-16].
The ﬁndings of this randomized clinical trial conﬁrm that
mobilization with the combination of GMþG-CSF reduced
the content of pDCs in the graft, and, additionally, the
numbers of CD3þ, CD4þ, and CD8þ cells were decreased by
approximately 30% in the grafts mobilized with the combi-
nation of GMþG-CSF.
We also observed a signiﬁcant enhancement in the rates
of T cell reconstitution among recipients of the grafts mobi-
lized with the GMþG-CSF combination, despite trans-
plantation of fewer donor T cells in the grafts these patients
received. The improved rates of T cell reconstitution as
measured by improved CD4 þ counts postallogeneic
Figure 4. (A) Recovery of CD3þ T cells posttransplantation based on the cytokine used for mobilization of the graft. There is no statistical difference between the
two cytokine groups. (B) Recovery of CD4þ T cells posttransplantation based on the cytokine used for mobilization of the graft. CD4þ recovery was more rapid
among recipients of GMþG-CSF mobilized grafts. (C) Recovery of CD8þ T cells posttransplantation based on the cytokine used for mobilization of the graft. There is no
statistical difference between the two cytokine groups. (D) Recovery of CD16þ cells posttransplantation based on the cytokine used for mobilization of the graft.
There is a statistical difference between the two cytokine groups at the 6-month posttransplantation time point for grafts mobilized with GMþG-CSF. (E) Recovery of
CD19þ cells posttransplantation based on the cytokine used for mobilization of the graft. There is no statistical difference between the two cytokine groups. (F)
Recovery of mDCs posttransplantation based on the cytokine used for mobilization of the graft. There is no statistical difference between the two cytokine groups. (G)
Recovery of pDCs posttransplantation based on the cytokine used for mobilization of the graft. There is no statistical difference between the two cytokine groups.
Values represent mean  standard error of the mean (SEM). *P < .05, **P < .01, ns ¼ P > .05.
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grafts could be explained by the presence of fewer pDC in
those grafts, as there is evidence from murine experiments
showing that DCs have roles not only in T cell engraftment
but also in peripheral homeostatic expansion of T cells after
bone marrow transplantation [1,17]. At nearly every tested
time point, there was improved CD4 þ recovery among the
GMþG-CSF mobilized group. It is possible that the use of
peritransplantation in vivo T cell depletion (antithymocyte
globulin or alemtuzumab; three patients in each treatment
arm) could affect this difference in T cell recovery, although it
was balanced in each treatment group. Additionally, there
was no ﬁxed, single conditioning regimen, and thus, it is
possible that the use of conditioning regimens inﬂuenced
T cell recovery posttransplantation.
The reported 5-year survival rate for all patients with
hematological malignancies undergoing allogeneic trans-
plantation from HLA-matched siblings is approximately 50%[18-24], and relapse remains the singlemost important cause
of death posttransplantation. In our trial, 21 of 50 patients
died from progressive disease [23-25], and no relapsed
patient was salvaged with long-term survival.
Currently, two methods can be used to modulate the
immunotherapeutic potential of transplantation (excluding
ex vivo manipulation of the graft or donor lymphocyte
infusion). Either one can use peritransplantation cytokines to
modulate DC and T cell content of the cellular graft or post-
transplantation administration of cytokines to inﬂuence
differentiation of DC and T cell subsets. Mobilization with
GM-CSF results in a shift in the content of precursor DCs
toward the mDC phenotype and Th1 polarization of T cells,
whereas mobilizationwith G-CSF results in differentiation of
HSCs toward the pDC phenotype that is associated with Th2
polarization [8,26-29]. In our study, the number of mDCs did
not increase in the group receiving GMþG-CSF, which is in
keeping with our previous data that suggest the addition of
Figure 4. (continued)
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more mDCs [10]. There is evidence that puriﬁed mDCs are
able to produce increased T cell proliferation after incubation
with alloantigens and challenging naïve T cells, whereas
pDCs, similarly treated, result in less robust T cell response to
alloantigen [10]. Consistent with our ownpreclinical data, we
demonstrated that G-CSF mobilized cells secreted increased
IL-2, suggestingmore regulatory Tcells producedwhen there
are higher numbers of pDCs [10]. Similarly, the increase in
secreted IL-12 by T cells mobilized with GMþG-CSF suggests
that fewer pDCs cells in the graft modulate more of a Th1Table 3
GVHD, Relapse, and Causes of Death
Variable CSF Arm
(Cohort A)
GMþG-CSF
Arm (Cohort B)
Total 25 25
GVHD
ACUTE (at least grade II) 10 7
Chronic 11 10
Death 2 1
Relapse 8 13
Infections (requiring hospitalization) 11 7
Death (total) 14 20
Relapse 8 13
Treatment-related mortality 6 7phenotype [10]. These data may explain why there is
enhanced T cell recovery among recipients of GMþG-CSF
mobilized grafts and favor the presence of a more “acti-
vated” T cell phenotype.
Our results with GM-CSF mobilized hematopoietic
progenitor cell grafts are consistent with prior studies
showing that G-CSF mobilizes more pDCs than GM-CSF
[10,28]. Although this trial was not powered to evaluate the
impact on any clinical endpoints, it is notable that fewer
numbers of cytokine-mobilized pDCs in the graft were not
associated with less relapse or improved survival. This may
be associated with the high number of patients with disease
at a high risk for relapse, withmany relapsing within the ﬁrst
100 days after transplantation and compromising the
assessment of progression-free survival and overall survival
in this study. However, the discrepancy between this study
and our previous report indicating an association of fewer
donor pDCs in an allogeneic bone marrow graft with
improved event-free survival may indicate important bio-
logical differences between pDCs when they are present in
different graft sources. The recent BMT-CTN (0201 study)
clinical trial [30] randomizing recipients of unrelated donor
transplantations to either bone marrow or peripheral blood
stem cell grafts suggested the bone marrow group receiving
greater numbers of pDCs cells had improved overall survival,
Figure 5. Kaplan-Meier survival curve for patients randomized to receive G-CSF or GMþG-CSF mobilized grafts.
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the CTN study was performed in an unrelated donor setting,
whereas our trial was noted among matched sibling donors
[30]. Although our study was designed as a pilot study to
demonstrate differences in laboratory endpoints and ach-
ieved that goal, the heterogeneity of conditioning regimens
and small sample size may have confounded the ability to
see clinical differences between the groups.
In conclusion, we observed that signiﬁcantly fewer pDCs
were mobilized by GMþG-CSF in apheresis products from
normal donors compared with G-CSF mobilization, and the
recipients of grafts mobilized by GMþG-CSF had a signiﬁ-
cantly different immune reconstitution pattern with
increased number of CD4 T cells. To optimize the speciﬁc
immunotherapeutic potentials of the HSCT graft, additional
studies of graft engineering through cytokine mobilization,
apheresis procedures, or selective ex vivo depletions or
enrichment of speciﬁc graft constituents should be further
investigated with regard to their effects on GVHD, graft-
versus-leukemia effect, and ultimately overall survival.
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